Approval · Notice of Compliance 8180 · 2006
STRATTERA: Notice of Compliance 8180
Issued July 27, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8180
- Date
- July 27, 2006
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strengths: 80 mg and 100 mg
- Therapeutic class
- Selective norepinephrine reuptake inhibitor
Products in this notice
Medicinal ingredients
- ATOMOXETINE HYDROCHLORIDE 80 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 100 MG per CAP